**Conclusions**

It was important that vascular endothelial function and ACS patients after the antioxidant probucol therapy. Endothelial dependent vasodilation reaction may be improved in the patients of ACS and remedy adjustment. Platelet activity further prove the necessity for case by case analysis patients; Residual platelet activities are also different; Even for the patients treated with probucol and ACS (r = 0.517, p < 0.001). The linear correlation analysis showed that plasma ox-LDL was a negative correlation with FMD in ACS patients was markedly diseased (p < 0.001). The FMD with probucol treatment group was significantly increased after 3 months compared to pretreatment (p < 0.05), while the level of ox-LDL in peripheral blood in ACS patients was markedly diseased (p < 0.01). The FMD with probucol treatment group was significantly increased compared to ACS routine treatment group (p < 0.05), while the level of ox-LDL was markedly diseased (p < 0.01). The linear correlation analysis showed that plasma ox-LDL was a negative correlation with FMD in ACS patients (r = -0.517, p < 0.001).

**Objective**

The study tested the antioxidant probucol for endothelial dependent vasodilatation reaction in the patients of ACS after received therapy.

**Methods**

51 ACS patients were divided randomly into a probucol treatment group (p) and a routine treatment group (C). Oxidised low-density lipoprotein (ox-LDL) was measured in peripheral blood by Sandwich ELISA method. The brachial arterial hyperaemia-induced flow mediated dilation (FMD) and sublingual nitroglycerin (NTG) mediated vasodilation were measured by high resolution ultrasound. These variables were analysed after received probucol 3 months.

**Results**

The level of FMD with probucol treatment group was significantly increased after 3 months compared to pretreatment (p < 0.05), while the level of ox-LDL in peripheral blood in ACS patients was markedly diseased (p < 0.01). The FMD with probucol treatment group was significantly increased compared to ACS routine treatment group (p < 0.05), while the level of ox-LDL was markedly diseased (p < 0.01). The linear correlation analysis showed that plasma ox-LDL was a negative correlation with FMD in ACS patients (r = -0.517, p < 0.001).

**Conclusions**

It was important that vascular endothelial function and endothelial dependent vasodilation reaction may be improved in the ACS patients of after the antioxidant probucol therapy.

**Results**

(1) Most of the people have a moderate maximal potential platelet activity except 7.1% with very low level and 14.3% with very high level potential platelet activity. (2) Through residual platelet activity detecting, it can be seen that patients who are sensitive in ADP pathway are not necessarily sensitive in AA pathway, and vice-versa. (3) The frequency percent from clopidogrel is 22.0% in inhibition rate of platelet activation less than 50% group, 18.8% in that more than 90% group. But that from aspirin is 14.6% and 26.5%, p = 0.0778 between the two pathways.

**Conclusions**

Potential platelet activities are not same in different patients; Residual platelet activities are also different; Even for the same patient, the platelet inhibition ability derived from Aspirin is different from that from Clopidogrel. These individual differences in platelet activity further prove the necessity for case by case analysis and remedy adjustment.

**Conclusions**

Hydrogen sulfide (H₂S) is found to be the third endogenous gaseous transmitter and plays an important role in many systems of organism. In cardiovascular system, H₂S is produced endogenously by cystathionine gamma-lyase (CSE). The CSE/H₂S system executes the physiological function of vasorelaxation, inhibition of vascular remodelling and cardioprotection. It is also concerned with variety of cardiovascular diseases such as hypertension and pulmonary hypertension. These results suggest that H₂S may be a novel cardiovascular functional regulator. And, at another hand, EPCs incorporate into the process of injured carotid endoendothelialisation. EPCs transplantation induces an increase in the circulating EPCs, accelerates the process of endothelial repairmen and reduces neoformation.

**Objective**

To study whether hydrogen sulfide has effects on endothelial progenitor cells (EPCs).

**Methods**

Total mononuclear cells (MNCs) isolated from bone marrow by density gradient centrifugation combined with adherence cells filtration were plated on fibronectin in coated culture dishes. After 7 days, adherent cells were kept with different concentrations of hydrogen sulfide for 48 h. EPCs proliferation, migration ability and adhesion assay was performed: EPCs apoptosis was induced by paclitaxel or serum starvation for 48 h, apoptosis was determined by TUNEL method and flow cytometry.

**Results**

Incubation of hydrogen sulfide dose dependently increased the number of EPCs (p < 0.01): hydrogen sulfide improved EPCs proliferation, migration and adhesion capacity (p < 0.01), and hydrogen sulfide could protect EPCs from paclitaxel or serum starvation-induced apoptosis (p < 0.01).

**Conclusions**

Hydrogen sulfide can increase the number of bone marrow derived EPCs and improve their biological characteristics.

**Objective**

To identify the risk factors of thromboembolism related to atrial fibrillation (AF) in difference structural heart disease and prevention of thromboembolism in AF with warfarin.

**Methods**

285 consecutive cases with AF, of which 110 were rheumatic heart disease (RHD) and 57 received prosthetic heart valve, and 53 received medicine therapy; of which 67 were hypertensive; of which 35 were patients without structural heart disease; of which 26 were patients with sick sinus syndrome who are receiving a pacemaker for symptomatic bradycardia of which 16 were ischaemic heart disease; of which 15 were dilated cardiomyopathy; of which 10 were congenital heart disease; of which 8 were other disease. Clinical data including gender; age; incidence of left atrial (LA) thrombus; incidence of thromboembolism or history of stroke or transient ischaemic attack (TIA); incidence of using warfarin and dose of warfarin; events of death.

**Results**

Incidence of left atrial (LA) thrombus (21.8%) and incidence of thromboembolism or history of stroke or transient ischaemic attack (TIA) (9.1%) in RHD group were significantly higher than those in other group (0–4%) (p < 0.001); incidence of using warfarin in RHD group (94.5%) were significantly higher than those in other group (61.7%) (p < 0.05).

**Conclusion**

Antithrombotic therapy is key and essential treatment in AF with one high or two moderate risk factors. RHD and prosthetic heart valve is high risk factor of LA thrombus and thromboembolism. 7 patients of AF with hypertension and ischaemic heart disease have thromboembolism, but only one patient by transcatheter echocardiography (TTE) have LA thrombus. So transesophageal echocardiogram is done. AF in whom anticoagulation is indicated to use warfarin. The target International Normalised Ratio (INR) range is 2.0–3.0, but while combination of warfarin and amiodarone the dose of warfarin is less than average dose.